Beranda › Limfoma Burkitt › Washington › Tacoma
Uji klinis Limfoma Burkitt di Tacoma, WA
3 studi untuk Limfoma Burkitt mencari peserta di lokasi sekitar Tacoma (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
- Mary Bridge Children's Hospital and Health Center, Tacoma
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
- Mary Bridge Children's Hospital and Health Center, Tacoma
- Madigan Army Medical Center, Tacoma
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- Mary Bridge Children's Hospital and Health Center, Tacoma
Uji klinis Limfoma Burkitt di kota lain
- Houston, TX21 studi
- Philadelphia, PA16 studi
- Milwaukee, WI16 studi
- Chicago, IL15 studi
- Cincinnati, OH13 studi
- New York City, NY13 studi
- Atlanta, GA12 studi
- Aurora, CO11 studi
- Seattle, WA11 studi
- Durham, NC10 studi
- Boston, MA10 studi
- Kansas City, MO10 studi
Studi lain di Tacoma
- Kanker Paru Non-Sel Kecil20 studi
- Kanker Payudara18 studi
- Kolitis Ulseratif15 studi
- Mieloma Multipel13 studi
- Kanker Prostat11 studi
- Penyakit Crohn11 studi
- Kanker Kolorektal9 studi
- Kanker Metastatik9 studi
- Melanoma7 studi
- Kanker Ovarium7 studi
- Kanker Lambung6 studi
- Kanker Esofagus6 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.